Welcome to our dedicated page for Valneva SE SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE filings document a foreign private issuer focused on prophylactic vaccines for infectious diseases. Its Form 6-K reports and Form 20-F disclosures cover consolidated financial results, product sales, research collaboration revenue, and business updates for marketed vaccines and clinical-stage programs, including Lyme disease, Shigella and chikungunya vaccine activities.
The filing record also includes material-event disclosures incorporated by reference into Form F-3 registration statements. These documents address material agreements, licensing and collaboration arrangements, capital-structure actions, shareholder voting and governance matters, risk factors, and clinical or regulatory updates for Valneva's vaccine candidates and commercial portfolio.
Valneva SE entered a senior term loan facility for an aggregate $500.0M, split into a $215.0M committed Tranche A (expected funded ~Oct 17, 2025) and up to $285.0M of uncommitted subsequent tranches subject to lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement; subsequent tranches are designated for general corporate and working capital including business development and permitted acquisitions. The loans mature five years after each tranche funding and carry a fixed interest rate of 9.00% with quarterly payments. There is a funding fee equal to 2.00% of principal and prepayment premiums of 3.00% if repaid before the third anniversary and 2.00% thereafter. Separately, Valneva reconfirms its Phase 3 Lyme vaccine trial remains on track; Pfizer targets BLA and MAA submissions in 2026 if data are positive, with VALOR outcomes expected in H1 2026 and a potential Pfizer launch in H2 2027.
Bpifrance Participations, EPIC Bpifrance, Bpifrance S.A., Caisse des d e9p f4ts et consignations (CDC) and CDC Croissance filed Amendment No. 3 to their Schedule 13D reporting positions in Valneva SE ordinary shares.
The filing shows Bpifrance Participations directly holds 8,639,886 ordinary shares and 17,259,364 voting rights; CDC Croissance holds 4,550,812 ordinary shares and voting rights. Aggregate voting rights reported for certain Reporting Persons are higher due to indirect holdings and joint ownership structures, with CDC reported as holding 21,810,176 voting rights. The percentages are calculated on 171,730,534 ordinary shares outstanding and 187,854,877 voting rights under U.S. law, producing a 9.2% voting-rights stake for Bpifrance Participations and an 11.6% voting-rights stake for CDC.
The Reporting Persons state the shares were acquired for investment purposes and that the apparent reduction in their percentage ownership results solely from an increase in outstanding shares, not from sales by the Reporting Persons. No reportable transactions occurred in the last 60 days and no plans currently exist for the corporate actions listed in Schedule 13D instructions, though they reserve the right to change investment intent.
Valneva reported consolidated revenues of €97.6 million for the six months ended June 30, 2025, with product sales rising to €91.0 million from €68.3 million a year earlier. Improved manufacturing performance lifted the product gross margin (excluding IXCHIQ) to 59.2%, supporting stronger cash generation despite a reported net loss of €20.8 million and an Adjusted EBITDA loss of €6.0 million. Cash and cash equivalents were €161.3 million.
Operationally, Valneva continued commercial rollouts and partnerships: IXCHIQ received marketing authorizations (including Brazil and the UK), a $32.8 million DoD supply contract for IXIARO was secured, an exclusive German distribution deal with CSL Seqirus was signed, and the VALOR Phase 3 Lyme trial completed full vaccination with Pfizer aiming for regulatory filings in 2026 subject to positive data. The company is advancing Shigella and Zika programs and expects to focus sales on proprietary vaccines while winding down third-party distribution.
Valneva SE filed a Form 6-K report on June 28, 2025, indicating the issuance of a press release dated June 26, 2025. The filing was signed by CEO and President Thomas Lingelbach.
This Form 6-K submission serves primarily as a notification of foreign issuer disclosure, with the company confirming it files annual reports under Form 20-F. The press release content (Exhibit 99.1) is referenced but not detailed in the main filing.
Notably, the information contained in this Form 6-K, including Exhibit 99.1, has been incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-286071), which could indicate potential future securities offerings or other significant corporate actions.